Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells by Eva M. Weissinger et al.
ORIGINAL RESEARCH
published: 23 April 2015
doi: 10.3389/fphar.2015.00076
Edited by:
Marina Deschamps,
Etablissement Français du Sang –
Bourgogne Franche-Comté, France
Reviewed by:
Adriana Maggi,
University of Milan, Italy
Marina Deschamps,
Etablissement Français du Sang –
Bourgogne Franche-Comté, France
*Correspondence:
Eva M. Weissinger,
Laboratory for Transplantation
Biology, Department
of Hematology/Hemostasis/Oncology/
Stem Cell Transplantation, Hannover
Medical School,
Carl-Neuberg-Straße 1, TPFZ, OE
6863, Room 5020, 30625 Hannover,
Germany
mischak-weissinger.eva@mh-
hannover.de
Specialty section:
This article was submitted to
Experimental Pharmacology
and Drug Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 01 December 2014
Accepted: 24 March 2015
Published: 23 April 2015
Citation:
Weissinger EM, Borchers S, Silvani A,
Provasi E, Radrizzani M,
Beckmann IK, Benati C, Schmidtke J,
Kuehnau W, Schweier P, Luther S,
Fernandez-Munoz I, Beutel G,
Ciceri F, Bonini C, Ganser A,
Hertenstein B and Stadler M (2015)
Long term follow up of patients after
allogeneic stem cell transplantation
and transfusion of HSV-TK
transduced T-cells.
Front. Pharmacol. 6:76.
doi: 10.3389/fphar.2015.00076
Long term follow up of patients after
allogeneic stem cell transplantation
and transfusion of HSV-TK
transduced T-cells
Eva M. Weissinger1*, Sylvia Borchers1, Anna Silvani2, Elena Provasi3,
Marina Radrizzani2, Irene K. Beckmann1, Claudia Benati2, Joerg Schmidtke4,
Wolfgang Kuehnau4, Patrick Schweier1, Susanne Luther1, Ivonne Fernandez-Munoz1,
Gernot Beutel1, Fabio Ciceri3, Chiara Bonini3, Arnold Ganser1, Bernd Hertenstein1,5 and
Michael Stadler1
1 Laboratory for Transplantation Biology, Department of Hematology/Hemostasis/Oncology/Stem Cell Transplantation,
Hannover Medical School, Hannover, Germany, 2 MolMed, Milano, Italy, 3 Cancer Immunotherapy and Gene Therapy
Program, San Raffaele Hospital, Milano, Italy, 4 Institute of Human Genetics, Hannover Medical School, Hannover, Germany,
5 Department of Hematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany
Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for
hematologic malignancies, but is hampered by severe complications, such as acute
or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selection
of stem cells reduces the risk of aGvHD, but also leads to increased infectious
complications and relapse. Thus, we studied the safety, efficacy, and feasibility of
transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials
between 2002 and 2007 and here we compare the results to unmodified donor
leukocyte infusion (DLI). The aim of these trials was to provide patients with the
protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched
donor setting with an option to delete transduced T-cells, if severe aGvHD occurred
within the trial period. Donor-T-cells were transduced with the replication-deficient
retrovirus SFCMM-3, expressing HSV-TK and the truncated LNGFR for selection
of transduced cells. Transduced cells were transfused either after day +60 (matched
donors) or on day +42 (haploidentical donors). Nine patients were included in the first
trial (MHH; 2002 until 2007), two were included in TK007 (2005–2009) and six serves
as a control group for outcome after haploidentical transplantation without HSV-TK-
transduced DLI. Three patients developed acute GvHD, two had grade I of the skin,
one had aGvHD on day +131 (post-HSCT; +89 post-HSV-TK DLI) grade II, which
was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after
transfusion of the transduced cells in all patients treated. Functionality of HSV-TK gene
expressing T-cells was shown by loss of bcr-able gene expression as well as by control
of cytomegalovirus-reactivation. To date, six patients have relapsed and died, two after a
second hematopoietic stem cell transplantation without T-cell depletion or administration
of unmodified T-cells. Eleven patients (seven post-HSV-TK DLI) are alive and well to date.
Keywords: gene transfer, horizontal, gene therapy, proteomics data, allogeneic stem cell transplantation, graft
vs. host disease
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Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is applied successfully to the treatment of many hematopoietic
malignancies, but remains limited by severe acute graft-versus-
host-disease (aGvHD). Despite prophylactic treatment of the
patients with immunosuppressive drugs after allo-HSCT, GvHD
is still associated with non-relapse mortality (NRM) and con-
tributes around 25% of NRM. (Mavroudis et al., 1998) T-cell
depletion of the graft by CD34-enrichment has been found
to be the most eﬀective method to prevent GvHD, but this
leads to an increased risk of leukemic relapse in about 80%
of patients (Horowitz et al., 1990; Gratwohl, 1994). Leukemic
relapse can be treated by donor leukocyte infusion (DLI;
Hertenstein et al., 1993; Kolb et al., 1995; Massenkeil et al.,
2003), providing evidence for an immunological graft-versus-
leukemia eﬀect (GvL). Thus, prophylactic transfusion of donor
T-cells has been included inmany protocols, despite the increased
risk for acute GvHD (Kolb, 2008). Acute GvHD contributes
signiﬁcantly to non-relapse morbidity and mortality (NRM),
thus prevention or control of this severe complication is neces-
sary.
T-cells are optimal targets for retroviral gene transfer and
stability of transduced T-cells has been shown even for sev-
eral years (Herve et al., 1992; Mavilio et al., 1994; Tiberghien,
1994; Contassot et al., 2000; Weissinger et al., 2000; Ciceri
et al., 2009; Borchers et al., 2011). The expression of sui-
cide genes has been shown to be eﬀective to control GvHD,
while retaining the positive eﬀects of T-cells like GvL-activity
(Bonini et al., 1997; Bondanza et al., 2006; Ciceri et al., 2009;
Borchers et al., 2011). Clinical trials with HSV-TK transduced
donor T-cells were initiated early in France, Italy and Germany
and have been previously published (Bonini et al., 1997; Ciceri
et al., 2009; Borchers et al., 2011). Transduced donor T-cells
were transfused either immediately after hematopoietic stem
cell transplantation (HSCT) on day 0 (Contassot et al., 2000;
Ferrand et al., 2000), on day +40 (Ciceri et al., 2009) or
after day +60 (Borchers et al., 2011). Eight patients from
the ﬁrst NGFR-HSV-TK-studies developed acute (n = 6) or
chronic GvHD (n = 2), which resolved after treatment with
GCV alone in seven of eight patients. Immunization against
HSV-TK epitopes was observed in one patient at MHH and
led to premature elimination of transduced T cells (Borchers
et al., 2011). The chance to get immunized strictly depended
on the presence of an active immune system at the time of
transfusion of transduced T-cells (Traversari et al., 2007). At
Hannover proteomic monitoring was added to predict pend-
ing, severe aGvHD to patients included after 2005 [10 of 12
acute myeloid leukemia (AML) patients; Weissinger et al., 2007,
2013]. Here, we analyzed the long term outcome of all patients
treated at MHH with genetically modiﬁed T-cells and com-
pare the outcome of mismatched transplantation in combina-
tion with prophylactic DLI to unmodiﬁed DLI-treatment of
relapse.
Materials and Methods
Study Protocol
Case Description
Seventeen patients, 15 with AML and two with chronic myel-
ogenous leukemia (CML), were transplanted from their HLA-
identical (n = 9) or haploidentical (n = 8) family donors
with CD34-enriched stem cells without further immunosup-
pression (Table 1). Eleven received transduced donor lym-
phocytes according to either one of the protocols (Figure 1).
The clinical protocols were approved by the ethic commit-
tee of the Hannover Medical School (protocol numbers 2157
or 3644) and by the national committee for somatic gene
therapy of the “Bundesärztekammer” (No 53 or No 76)
and the Paul-Ehrlich-Institute (1274). In addition, both tri-
als were registered at the German register of gene therapy
trials.
Conditioning and Hematopoietic Stem Cell
Transplantation
T-cells were harvested from all donors after informed con-
sent and shipped to Milano for transduction. Eleven patients
received total body irradiation (TBI; 12 Gy) and cyclophos-
phamide (120 mg/kg) followed by a CD34-enriched stem cell
graft from matched related donors (MRDs; Table 1). Donors
received G-CSF (2× 5µg/kg daily) for 4–5 days and blood leuko-
cytes were collected at the Institute for Transfusion Medicine
(MHH; Borchers et al., 2011). CD34-selection was performed
under GMP conditions using the CliniMACS-system (Miltenyi;
Bergisch Gladbach, Germany) at the Center for Cellular Therapy
(former Cytonet, Hannover, Germany). At least 3.9 × 106/kg
CD34-positive cells were transplanted on day 0, andCD3+ T-cells
were usually below 1× 104 cells/kg body weight (Table 1). CD34-
selection was the only GvHD prophylaxis. Missing informed
consent, acute GvHD grade II or more, life threatening infec-
tions, or relapse at the time of transfusion were exclusion criteria
for gene therapy. Relapse and declining donor chimerism were
treated with additional, non-transduced DLI (see Table 2). One
patient (UPN 1505) received a second transduced DLI to treat
relapse.
Description of the Retroviral Vector and the
Transduction Protocol
Lymphapheresis material was obtained from 11/17 donors and
shipped to MolMed (Italy) by courier for transduction. The
replication-deﬁcient, retroviral vector SFCMM-3 encodes the
HSV-TK gene that confers sensitivity to GCV, and the trun-
cated low aﬃnity nerve-growth-factor-receptor gene (LNGFR)
serving as a positive selection marker and transduction proto-
cols have been described previously (Mavilio et al., 1994; Bonini
et al., 2007; Ciceri et al., 2007, 2009; Borchers et al., 2011)
Brieﬂy, cells were expanded with OKT-3 (30 ng/ml) in RPMI1640
with 5% autologous plasma and 100 U/ml IL-2 (Chiron, USA)
for 72 h. Cells were transduced by spin-inoculation with
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SFCMM-3-supernatant twice within 24 h in the presence of
4 µg/ml protamine sulfate and expanded for 48 h. Transduction
eﬃciencies were determined by FACS and subsequently the
cells were selected using a monoclonal antibody (anti-LNGFR-
antibody, Roche, Mannheim, Germany) and immunomagnetic
beads (Dynabeads; Verzeletti et al., 1998). Transduced and
selected cells were cryopreserved, while safety tests (as approved
by the authorities) were accomplished and shipped to Hannover
for transfusion (Table 1).
Monitoring for the Presence of Transduced
T Lymphocytes
Characterization and ex vivo detection of circulating transduced
cells was planned at weekly for the ﬁrst month 1, 2, 3, 4, 8, 12,
16, 20, 24, at 9 months, 12 months, and yearly thereafter. The fol-
low up for three patients is now more than 12 years (Tables 2 and
3). Flow cytometry (FACS; Coulter, Germany) was performed to
examine the frequency and phenotype of the transferred gene-
modiﬁed T-cells in vivo using mAbs speciﬁc to LNGFR (Roche,
Mannheim, Germany), CD3, CD4, and CD8 (Coulter), respec-
tively. Immune reconstitution was analyzed for B-, T-, natural
killer cells, macrophages, and monocytes.
The presence of gene modiﬁed T-cells was conﬁrmed by poly-
merase chain reactions (PCRs) with primers for the HSV-TK and
the LNGFR-gene, as described (Borchers et al., 2011).
HSV-TK-Gene, Donor-Chimerism, and T-Cell
Receptor (TCR)-Vβ Family Expression
Transduced cells were analyzed at above mentioned time points
and yearly thereafter for the presence of HSV-TK gene expres-
sion. To increase the likelihood to detect gene modiﬁed cells,
TABLE 1A | Patient clinical characteristics: all patients were transplanted
with CD34-enriched donor cells from their HLA-identical siblings or
haploidentical family donors.
Table 1: clinical data All patients
(n = 17)
Table 1 All patients
(n = 17)
Age 35 (18–63) GvHD-Pro
Disease CSA/MTX 0
Acute (AML, ALL, sAML) 15 CSA/MMF 1
Chronic (MDS, MPS,
CML, CLL)
2 TCD 11
Status ATG, Thymo 14
CR 1/CP1 14 None 3
CR 2 or higher 2 Donor
No CR (untreated,
relapse, refr.)
1 Related 17
Conditioning Unrelated 0
Myeloablative (TBI/Cy) 9 HLA-match
RIC 8 Matched 9
Graft Mismatched 8
PBSC 17 Gender
Bone marrow 1∗ Female/male 9/8
HSV-TK DLI 11 m/f donor 4
None 6 Alive 11
Donors’ gender and age are shown under “donor.” Transduced T-cells were
transfused after day +60 or day +42 (MMRD). ∗PBSC (CD6-depleted) +BM. TA
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FIGURE 1 | Clinical trial flow chart. Prior to G-Lymphapheresis were
obtained prior to G-CSF-stimulation of the donor and shipped to MolMed for
transduction by courier. After G-CSF-stimulation peripheral blood stem cells
(PBSCs) were collected and CD34+ cells were selected and transplanted on
day 0. The recipient of matched related donor PBSC received conditioning
treatment with total body irradiation (TBI; 12 Gy) and cyclophosphamide
(120 mg) and ATG (30 mg/kg). The recipients of the mismatched related
donor PBSC received conditioning with Fludarabine, Melphalan, Thiotepa,
and anti-thymoglobulin (ATG; 60 mg/kg). Lymphapheresis cells were
transduced with SCFMM3 , and shipped to Hannover prior transfusion.
HSV-TK DLI (1 × 107 cells/kg BW) were administered either after day +60
(MRD) or on day +42 (MMRD; 1 × 106/kg BW).
PBMNC were enriched for CD3+/CD4+ and CD8+ T-cells.
Genomic DNA was isolated using the QIAamp DNA MinElute
Kit (Qiagen, Hilden) and ampliﬁed. A nested PCR had been
developed for the detection of HSV-TK gene (Borchers et al.,
2011). The PCR was run on 1.2% agarose gels and analyzed.
A summary of the results is shown in Table 3.
RT-PCR-Analyses
RNA was isolated from PBMNC or CD3-enriched, CD3+/CD8+
and CD3+/CD4+ T-cells transcribed into cDNA. TCR-repertoire
analyses were done using 25 vß- family speciﬁc primers, includ-
ing controls for the constant region of the TCR and human
ß-actin, as described (Naumov et al., 1995). RT-PCR for detec-
tion of the bcr-abl fusion transcript was performed as proposed
by the BIOMED-1 nested PCR on Taqman concerted action (Van
Dongen et al., 1999; Borchers et al., 2011). PCR was performed
with the T3 thermocycler (Biometra). Donor chimerism was ana-
lyzed by PCR ampliﬁcation of highly polymorphic short tandem
repeat (PCR-STR) sequences in peripheral blood and/or bone
marrow samples as described earlier (Briones and Amils, 1998).
Results
12 Years of Successful Transduced T-Cell
Transfer at MHH
Seventeen patients were transplanted from MRD or mismatched
related donors (MMRDs) and eleven received gene-modiﬁed
donor T-cells on day +42 (n = 2) or after day +60 (n = 9)
after HSCT. Clinical and demographic data are summarized
in Table 1. Lymphaphereses were prepared from 11 donors
and shipped to MolMed for transduction with SCFMM-3 and
enrichment for transduced T-cells with magnetic immunobeads
yielded purities of more than 90% for LNGFR+ cells, rang-
ing from 91 to 99.1%. The patients were scheduled to receive
transduced T-cells on day +42 or day +60, respectively, after
matched (MRD) or haploidentical (MMRD) HSCT, if the clin-
ical situation of the patients allowed transfusion. The ﬁrst
nine patients (MRD; Table 1B), received the T-cell trans-
fusion by day +107 after HSCT (range: 71–330), the two
patients receiving cells from MMRD received the HSV-TK
DLI on day +42 (Table 1C). The immune reconstitution
for lymphocytes was 640 CD3+ T-cells/µl (range: 150–1000
cells/µl) after MRD HSCT and zero for the MMRD transplant
recipients.
Transfusion of Genetically Modified Donor
Lymphocytes or Untransduced
Seven patients had residual host cells prior to DLI. In six patients
donor chimerism progressively increased after DLI and full donor
chimerism was obtained in three patients, thus suggesting that
the infusion of genetically modiﬁed donor lymphocytes may
have facilitate HSCT engraftment. In T-depleted transplanta-
tion the achievement of full chimerism is particularly diﬃcult.
In accordance with this hypothesis, expansion of transduced
donor lymphocytes often preceded the improvement of donor
chimerism.
LNGFR-positive cells were detected by FACS (up to 6.6%
of CD3+ cells) for at least 6 months after transfusion. In
two MMRD-recipients all CD3+ T-cells detected were trans-
duced and of donor-origin, as expected. Patient UPN1505
reactivated CMV early after MMRD-HSCT. Transduced cells
were transfused on day +42 from the CMV-seropositive donor
and by day +77 CMV-CTL (n = 2) from the MMRD were
detected (Table 1D). This was followed by an expansion of
the CMV-CTL and led to the control of CMV-reactivation
(Table 1D). UPN 1505 also developed aGvHD grade II (day
+131; Tables 1C,D). GCV was given at 5 mg/kg body weight
and as a result aGvHD was cleared. Unfortunately the patient
developed relapse and died despite a second transfusion of
HSV-TK transduced DLI on day +222 (Tables 1C and 2).
Patient 1550 did not receive any DLI, but CMV-CTL could
be detected by day +44, providing protection against CMV-
reactivation. HSV-TK gene expression was analyzed until last
follow-up in all patients and a summary of the data is shown
Table 3. The longest follow-up for HSV-TK transduced cells
was 7 years after HSCT (UPN1190), followed by 3 years
(UPN914), whereas HSV-TK transduced cells were detectable for
almost 2 years in another 6. One patient UPN919 lost HSV-
TK gene expression after 22 months, in the absence of GCV
treatment due to an immunization against transgene products
(Borchers et al., 2011). Thus, seven patients had detectable lev-
els of HSV-TK for more than 1 year after HSCT, two died
prior to the ﬁrst year after HSCT (Table 3). PCR for HSV-
TK gene expression and donor chimerism are done yearly
for all patients alive. To date, six patients have a follow up
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TABLE 2 | Summary of transduced and non-transduced DLI: peripheral blood of all patients was screened routinely for the presence of transduced cells
with FACS and PCR.
UPN Gebdat Age_HSCT
(1st and 2nd)
DLI DLI-days-
post-HSCT
Cells/kg BW
914 06.07.1957 45 DLI(HSV-TK) 71 1 × 10E7
914 06.07.1957 45 DLI chimerism 178 1 × 10E7
91A 06.07.1957 45 DLI chimerism 249 1 × 10E7
91A 06.07.1957 45 DLI chimerism 329 3 × 10E7
91A 06.07.1957 45 DLI chimerism 406 5,3 × 10E7
919 03.02.1967 35 DLI(HSV-TK) 87 4 × 10E6
1021 02.12.1963 39 DLI(HSV-TK) 113 1,3 x10E7
1021 02.12.1963 39 DLIrelapse 2535 1,8 × 10E7
1021 02.12.1963 39 DLIrelapse 2564 1,12 × 10E8
1021 02.12.1963 39 DLIrelapse 2592 2 × 10E8
1040 28.12.1952 50 Stemcell boost 191 6 × 10E6 CD34+
1040 28.12.1952 50 DLI(HSV-TK) 330 1 × 10E7
1040 28.12.1952 53 DLIprophylaxis 268 1,03 × 10E6
1040 28.12.1952 53 DLIprophylaxis 304 5 × 10E6
1040 28.12.1952 53 DLIprophylaxis 339 1 × 10E7
1040 28.12.1952 53 DLIrelapse 535 5 × 10E7
1040 28.12.1952 53 DLIrelapse 563 1 × 10E8
1040 28.12.1952 53 DLIrelapse 612 1,23 × 10E8
1048 23.01.1965 38 DLI(HSV-TK) 100 1,5 × 10E7
1108 18.02.1953 51 DLI(HSV-TK) 126 4 × 10E6
1159 23.12.1968 35 DLI(HSV-TK) 136 7,5 x10E6
1190 10.03.1966 38 DLI(HSV-TK) 129 1 × 10E7
1208 06.12.1953 51 DLI(HSV-TK) 73 1,3 × 10E7
1208 06.12.1953 51 DLIrelapse 519 1,8 × 10E7
1269 10.04.1987 18 DLIrelapse 377 5,38 × 10E4
1269 10.04.1987 18 DLIrelapse 405 1,3 × 10E5
1269 10.04.1987 18 DLIrelapse 433 4,7 × 10E5
1269 10.04.1987 18 DLIrelapse 461 1,27 × 10E6
1269 10.04.1987 18 DLIrelapse 488 5 × 10E6
1269 10.04.1987 18 DLIrelapse 517 1 × 10E7
1269 10.04.1987 18 DLIrelapse 545 5,03 × 10E7
1438 13.10.1972 34 No na
1550 25.04.1982 25 No
1505 16.12.1983 23 DLI(HSV-TK) 48 1 × 10E6
1505 16.12.1983 23 DLI(HSV-TK) therapy 222 1 × 10E6
1551 18.08.1975 32 DLI(HSV-TK) 42 1 × 10E6
The number of transduced (first DLI) and non-transdcued DLI (for loss of chimerism or relapse) are shown as number of transduced cells (CD3+ cells) or as number of
leukocytes transfused per kg body weight.
of more than 6 years patients, two patients had been treated
12 years ago and are both alive and well. None of the sur-
viving patients show HSV-TK expression at last follow up
(Table 3).
Discussion
Our data show the long term safety and eﬃcacy of retroviral
gene transfer in mature T-cells. The transfusion of transduced
cells was tolerated well in all patients with no reported toxi-
cities. Replication competent particles have not been detected
and in general gene expression is lost after about 2 years. Ciceri
et al. (2009) have recently shown that transfusion of transduced
CD3+ cells after haploidentical transplantation allows for opti-
mal expansion of transduced cells (Garin et al., 2001). Long
term transgene expression for more than 1 year was observed
in seven of nine patients, ﬁve had HSV-TK expressing cells
for more than 1 year. Two patients transplanted from mis-
matched donors died prior to day +365. Eﬃcacy of the cells
had been demonstrated by control of bcr-abl positivity, donor-
chimerism conversion and in the MMRD-transplanted patient
1505 a cytomegalovirus-reactivation was controlled by the expan-
sion of HSV-TK-transduced donor T-cells.
TK007 protocol called for haploidentical (MMRD) HSCT
and eight patients were transplanted from haploidentical donors
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TABLE 3 | Long term follow up of PCR for TK-gene: summarizes the results obtained with PCR on HSV-TK gene expression.
UPN Days post-HSCT Days post-DLI Years follow-up Material for cDNA HSV-TK PCR result Comments
914 1155 1084 3,0 PBMNCs Positive
914 4161 4090 11,2 CD3+ Negative
914 4526 4455 12,4 CD3+ Negative Alive
919 3664 3577 9,8 CD3+ Negative
919 4165 4078 11,2 CD3+ Negative
919 4530 4443 12,2 CD3+ Negative Alive
1021 857 744 2,0 PBMNCs Positive
1021 2831 2718 7,4 CD3+ Negative
1021 3868 3755 10,60 CD3+ Negative Alive
1040 687 357 1,0 CD3+ Positive
1040 974 644 1,8 PBMNCs Positive
1040 1057 727 2,90 CD3+ Negative Relapse;
re-transplantation; died
1048 791 691 1,9 PBMNCs Positive
1048 1002 902 2,5 PBMNCs Negative
1048 2787 2687 7,64 CD3+ Negative Alive
1108 723 597 1,6 PBMNCs Positive
1108 807 681 1,9 PBMNCs Positive
1108 3598 3472 9,5 CD3+ Negative Alive
1159 365 229 0,6 PBMNCs Negative
1159 640 504 1,4 CD3+ Negative
1159 3382 3246 8,9 CD3+ Negative Alive
1190 2398 2269 6,2 CD3+ Negative
1190 2767 2638 7,2 CD3+ Positive
1190 3144 3015 8,3 CD3+ Negative Late relapse, alive
1208 476 403 1,1 PBMNCs Positive
1208 484 411 1,1 PBMNCs Positive
1208 512 439 1,2 PBMNCs Positive Relapse;
re-transplantation; died
1505 221 173 0,5 CD3+ Positive
1505 250 202 0,6 CD3+ Positive
1505 277 229 0,6 CD3+ Negative Died relapse
1551 114 72 0,2 CD3+ Positive
1551 148 106 0,3 CD3+ Negative
1551 220 178 0,5 CD3+ Positive Died
UPN# (unique patient identification number), followed by sample date and days after allogeneic HSCT, days after DLI, Tx date (date of transplantation), Days post 1st
or 2nd DLI (where appropriate), material from which RNA or DNA were obtained (PBMC: peripheral blood mononuclear cells; CD3: CD3-positive T-cells) and results of
HSV-TK-PCR. DNA-isolation and HSV-TK-PCR were done as described in Section “Materials and Methods.”
(MMRD) at Hannover. Only two patients received transduced
DLI, the others were observed as control group for MMRD-
HSCT and HSV-TK transfer. All patients receiving transduced
T-cells expressed the transgenes for at least 1 year or until last
follow up, if patients died prior to day +365 (Table 3). In one
patient an immunization against the transgenes had occurred
thus the cells were lost earlier (Borchers et al., 2011).
We have not detected non-functional HSV-TK genes in pour
small patient cohort to date (Mercier-Letondal et al., 2008).
LNGFR expression as a selection marker allows rapid selection
of the transduced cells, which may be favorable for the pheno-
type of the transduced cells, leaving the T-cell receptor repertoire
of the transduced cells relatively intact (Borchers et al., 2011)
as compared to more time consuming selection methods with
antibiotic resistance genes.
In our studies, two of the 11 patients treated with HSV-
TK transduced T-cells so far developed aGvHD grades I or II,
respectively. The patient (UPN1505) had developed acute GvHD
grade II and was treated successfully with GCV, thus giving a
conﬁrmation of the feasibility of the HSV-TK gene transfer for
control of acute GvHD by GCV treatment. The persistence of
the transduced cells over about 2 years in the majority of the
patients suggests that the transduced cells were able to engraft and
expand. The expansion of the transduced cells could be linked
to clinical data, such as viral infections or was seen as response
to declining donor chimerism, suggesting function of transduced
cells. After transfusion of the transduced cells one patient reac-
tivated CMV early after HSCT (day +20) and upon transfusion
of the transduced cells the CMV-reactivation was cleared. In one
patient (UPN919) HSV-TK transduced were lost after 22months.
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A low rate of immune mediated elimination of transduced cells
was observed in our studies, suggesting that early add-back of
TK-expressing cells is permitted, despite intrinsic immunogenic-
ity of the viral-derived suicide gene.
In summary, the data presented here indicate that the use of
SFCMM-3 transduced T-cells can be monitored in a clinical set-
ting and is currently safe, eﬃcient, and adequate for the proposed
treatment of GvHD.
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